Intellectual Property India Publishes Patent Application for 'Glycosyl-Modified Fusion Protein, Nucleic Acid Molecule, Expression Vector, Host Cell, And Use' Filed by Kaimi Biomedicine (CHENGDU) Co. Ltd.

MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517002997 A) filed by Kaimi Biomedicine (CHENGDU) Co. Ltd., Sichuan, China, on Jan. 13, for 'glycosyl-modified fusion protein, nucleic acid molecule, expression vector, host cell, and use.'

Inventor(s) include Shi, Yuenian; Yu, Bo; and Zhang, Bo.

The application for the patent was published on June 6, under issue no. 23/2025.

According to the abstract released by the Intellectual Property India: "A glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell, and a use. The glycosyl-modified fusion protein comprises a murine Fc variant and a polypeptide antigen; the murine Fc variant is obtained by carrying out amino acid mutation and non-mammalian glycosylation modification on a murine Fc fragment; the murine Fc variant comprises at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332; the non-mammalian glycosylation modification does not comprise sialic acid modification; site numbering is carried out on the basis of an EU numbering system. The murine Fc variant improves the binding and DC activation of the murine Fc fragment and a DC cell, and comprises proliferation and activation of specific T cells."

The patent application was internationally filed on June 28, 2024, under International application No.PCT/CN2024/102292.

Disclaimer: Curated by HT Syndication.